**Core Concept**
The EMA-CO regimen is a chemotherapy protocol used to treat choriocarcinoma, a type of gestational trophoblastic disease. This regimen combines three main components: Etoposide, Methotrexate, and Actinomycin D, along with Cyclophosphamide and Vincristine.

**Why the Correct Answer is Right**
The EMA-CO regimen is a modified version of the EMA regimen, with the addition of Cyclophosphamide and Vincristine to enhance its effectiveness against choriocarcinoma. Etoposide and Actinomycin D work synergistically to induce DNA damage and inhibit cell growth, while Methotrexate targets rapidly dividing cells. Cyclophosphamide and Vincristine add to the regimen's cytotoxic effects, making it more effective against this aggressive tumor.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not a part of the EMA-CO regimen.
**Option B:** This option is incorrect because it is not a standard component of the EMA-CO regimen.
**Option C:** This option is incorrect because it is not a recognized component of the EMA-CO regimen.

**Clinical Pearl / High-Yield Fact**
The EMA-CO regimen is a critical component of choriocarcinoma treatment, and its effectiveness is often measured by the β-hCG level. A significant reduction in β-hCG levels is a key indicator of treatment success.

**Correct Answer:**
Correct Answer: D.